rare diseases

The BioPontis Alliance hopes its new model for bringing patients’ insights and industry expertise to bear in preclinical research will reduce risk and promote development of rare disease therapies. The Alliance has funding from a Belgian charity for its first project

It’s a virtuous circle: New approval processes put in place by the European Medicines Agency are de-risking drug development, promoting investment in early-stage biotech and meeting unmet medical needs, says Paul Morton